(Q28278620)
Statements
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (English)
0 references
24 November 2012
0 references
380
0 references
1829-39
0 references
9856
0 references